AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03408743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expectancies, descriptive norms, benefits
Description: Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
Study NCT03408743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expectancies, descriptive norms, benefits, efficacy
Description: Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
Study NCT03408743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expectancies, descriptive and injunctive norms
Description: Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
Study NCT03408743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expectancies, descriptive & injunctive norms, efficacy
Description: Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
Study NCT03408743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expectancies, descriptive & injunctive norms, benefits
Description: Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
Study NCT03408743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expectancies, descriptive & injunctive, benefits, efficacy
Description: Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
Study NCT03141710 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20 ml of prebiotic per day
Description: 12 volunteers will take 20ml of prebiotic per day for 12 weeks
Study NCT01337830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ariva® Silver Wintergreen
Description: Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
Study NCT01337830 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Silver Wintergreen
Description: Comparator product containing 6 mg silver salt and no tobacco (i.e., no nicotine), administered orally as a single dose.
Study NCT04360174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-TIC
Description: OTX-TIC implant is injection in the anterior chamber of the eye
Study NCT03452046 — intervention group
Intervention type: OTHER
Intervention: IVC diametres
Study NCT01919684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LGD-6972
Study NCT01919684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Captisol®)
Study NCT02876991 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sodium fluoride PET
Description: Sodium fluoride Pet is realized maximum after 4 weeks from choline PET (inclusion).~Injection of 4MBq 18F-FNa/kg of body weight is followed after 60 min (± 5 min) by acquisition of images on Biograph 6 PET/CT scanner (SIEMENS).~Data from sodium fluoride PET are interpreted independently and blind from other data by 3 medical doctors (2 at hospital of Nancy and 1 at hospital of Strasbourg) (for inter-judge reproducibility); a second interpretation of data is consensually realized by 2 of 3 readers, limited to discordant analyses (metastatic status or not, and/or number of lesions); results from this second interpretation are final results.
Study NCT04699513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation Mode (airway pressure release ventilation )
Description: Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that alternates between two levels of continuous positive airway pressure (CPAP) support and allows spontaneous respiratory effort at either CPAP level. It is considered as an alternative, life-saving modality in patients with acute respiratory distress syndrome (ARDS) that struggle for oxygenation.
Study NCT03184194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab-daratumumab
Description: nivolumab-daratumumab will be given without low-dose cyclophosphamide until progression
Study NCT03184194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab-daratumumab with low-dose cyclophosphamide
Description: nivolumab-daratumumab with low-dose cyclophosphamide will be given until progression
Study NCT03931473 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bed nets
Description: Next-generation bed nets combining insecticides with different modes of action or a standard pyrethroid bed net
Study NCT03931473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bed nets
Description: Next-generation bed nets combining insecticides with different modes of action or a standard pyrethroid bed net
Study NCT00369070 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 15 mg/kg bevacizumab, delivered via intravenous (IV) infusion once every 3 weeks
Study NCT00369070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 706
Description: subjects in Arms A and B will take AMG 706 orally in one of two dosing regimens over each 21-day cycle: •Arm A: 125 mg once daily (QD) •Arm B: 75 mg twice daily every 12 ± approximately 1 hour for 5 days followed by a 2 day treatment free period every 7 days
Study NCT00369070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: All subjects will receive a paclitaxel chemotherapy regimen (paclitaxel 200 mg/m2) on day 1 of each 3-week cycle for a maximum of 6 cycles.
Study NCT00369070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: All subjects will receive a paclitaxel chemotherapy regimen (paclitaxel 200 mg/m2) on day 1 of each 3-week cycle for a maximum of 6 cycles.
Study NCT00369070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: All subjects will receive carboplatin chemotherapy regimen (carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3-week cycle for a maximum of 6 cycles.
Study NCT00369070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: All subjects will receive carboplatin chemotherapy regimen (carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3-week cycle for a maximum of 6 cycles.
Study NCT00847769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High velocity, low amplitude stretch
Description: This group (n=9) will receive talocrural traction manipulation. With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
Study NCT00847769 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Slow, mobilization stretch
Description: This group (n=9) will receive talocrural traction mobilization. With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating investigator's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
Study NCT00847769 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Passive Positioning
Description: This group (n=9) will receive the manual therapy control intervention. This will consist of the same patient and clinician preparation for the mobilization/manipulation techniques. However, a single standardized treating investigator will simply maintain passive ankle positioning for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force characteristic of the intervention received by the other 2 comparison groups.
Study NCT06586788 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Eyelink Portable Duo
Description: Eye-tracking data will be collected using a commercially-available remote eye-tracking system (Eyelink Portable Duo). Eye movements and pupil diameter will be collected while participants view a series of developmentally appropriate pictures and movies. The eye-tracker consists of two cameras; one that monitors eye movements and a second scene camera that monitors head movements, which permits eye tracking to take place without any equipment touching the child. Children will be asked to sit in highchair or on a caregiver's lap and will face a computer monitor. After a sticker is applied to the child's forehead and brief eye-movement calibration completed, next visual stimuli (i.e., pictures and videos) will be presented on a laptop computer monitor that is placed at approximately 60-80cm from the child. The eye tracking portion of the visit will last approximately 15 minutes or until the child is no longer able to attend to pictures/videos.
Study NCT06586788 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Integrated PCP Diagnosis and Eye-tracking Biomarker
Description: A Classification and Regression Tree (CART) Analysis, based on recursive partitioning, was used to determine which combination of variables (EE Hub PCP diagnosis, diagnostic certainty, composite biomarker, and biomarker frequency \[sum of all individual biomarkers (0-6) that exceeded the 95% specificity threshold for each child\]) best predicted reference standard autism diagnosis.
Study NCT02490891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RGD K5 PET scan
Description: PET scan with a tracer specific for angiogenesis (RGD K5) will be performed before and after 2 cycles of chemotherapy
Study NCT02679534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hand massage
Study NCT02679534 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hand holding
Study NCT02679534 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: application of unscented hypoallergenic cream
Study NCT02679534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: application of unscented hypoallergenic cream
Study NCT02679534 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: environmental adjustments
Study NCT02679534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: environmental adjustments
Study NCT02679534 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: environmental adjustments
Study NCT01338558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 5 mg/kg iv on Day 1 of each 2-week cycle until disease progression, unacceptable toxicity or withdrawal of consent
Study NCT01338558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: 400 mg /m2 iv on Day 1, followed by 250 mg/m2 every week until disease progression, unacceptable toxicity or withdrawal of consent
Study NCT01338558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Standard mFOLFOX6 chemotherapy, 2-week cycles until disease progression, unacceptable toxicity or withdrawal of consent
Study NCT01338558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: Standard mFOLFOX6 chemotherapy, 2-week cycles until disease progression, unacceptable toxicity or withdrawal of consent
Study NCT03055611 — intervention group
Intervention type: DRUG
Intervention: ELOCTA
Description: Extended half-life factor VIII product
Study NCT03055611 — intervention group
Intervention type: DRUG
Intervention: ALPROLIX
Description: Extended half-life factor IX product
Study NCT01052909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride tablets 1 mg
Study NCT01052909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Glimepiride tablets 1 mg
Study NCT04147767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholesterol Reducing Strawberry Yogurt Drink (Tesco Ltd)
Description: Ingredients: Skimmed Milk, Strawberry Juice from Concentrate (5%), Plant Sterols Ester (3.4%)\*\*\*, Sugar, Maize Starch, Flavourings, Colour (Anthocyanins), Starter Culture including Bifidobacterium (Milk), Thickener (Carob Gum), Sweetener (Sucralose), Milk Proteins.~\*\*\* Equivalent to 2% Free Plant Sterols
Study NCT04147767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low Fat Strawberry Yogurt Drinks (Morrisons Ltd)
Description: Ingredients: Yogurt (Milk), Water, Sugar, Strawberry Purée (1%), Modified Maize Starch, Carrot Concentrate, Flavouring, Acidity Regulator (Citric Acid), Vitamin C, Colour (Paprika Extract), Sweetener (Sucralose), Vitamin D, Vitamin B6.
Study NCT03966690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isokinetic leg extension/-flexion on a legpress device
Description: Maximum strength and rate of leg-flexion /-extension during legpress exercise
Study NCT03966690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isokinetic leg extension/-flexion on a legcurl device
Description: Maximum strength and rate of leg-flexion /-extension during legcurl exercise
Study NCT03264768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endobronchial valves
Description: A ambulatory diagnostic bronchoscopy under general anesthesia will evaluate the presence or absence of collateral ventilation . The targeted lobar airway is temporarily occluded by means of a balloon catheter, which blocks inspiratory flow but allows expiratory flow, in order to assess whether the air flow gradually declines to zero, meaning absence of collateral ventilation. Only in case collateral ventilation is excluded, a therapeutic bronchoscopy will be scheduled to insert the one-directional endobronchial valves in the targeted lobar airways. We will only perform a unilateral intervention during which we will treat one or maximal two lobes at one side.
Study NCT03264768 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity tele coaching
Description: 3 month physical activity tele coaching intervention consisting of a project tailored smartphone application in combination with a step counter providing direct feedback.
Study NCT03264768 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: physical activity tele coaching
Description: 3 month physical activity tele coaching intervention consisting of a project tailored smartphone application in combination with a step counter providing direct feedback.
Study NCT03264768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Description: Patients not eligible for endoscopic lung volume reduction (or non responders of this intervention) can be referred for surgical lung volume reduction. With this procedure, the most emphysematous parts of the lungs will be surgically removed.
Study NCT03264768 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lung volume reduction surgery (LVRS)
Description: Patients not eligible for endoscopic lung volume reduction (or non responders of this intervention) can be referred for surgical lung volume reduction. With this procedure, the most emphysematous parts of the lungs will be surgically removed.
Study NCT03804515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-labeled poziotinib
Description: a single capsule containing 12 mg of 14C-labeled poziotinib (approximately 90 to 110 μCi) will be administered orally
Study NCT02128165 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BMI more than 45 BMI
Description: Air filled gastric balloon (Heliosphere) those BMI above 45
Study NCT02128165 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BMI less than 45 BMI
Description: Air filled gastric balloon (Heliosphere) those BMI below 45
Study NCT00944281 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LNS-Zn5
Description: Daily consumption of 20 g LNS containing 5 mg of zinc and daily placebo supplement
Study NCT00944281 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LNS-Zn10
Description: Daily consumption of 20 g LNS containing 10 mg of zinc and daily placebo supplement
Study NCT00944281 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: LNS-Zn0
Description: 20 g of LNS containing 0 mg of zinc and a daily placebo supplement
Study NCT00944281 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Suppl-Zn5
Description: Daily 5 mg zinc supplement ant consumption of 20 g LNS containing 0 mg of zinc
Study NCT01926522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technological Rehabilitation
Description: The length of stride of reference used during the exercise is personalized and depends on the height of patients. Each patient carries out the feedback for 20 minutes with the aim of generating the most symmetric and regular gait.~Patients, with the dynamometer, work on strengthening of flexor and extensor muscles with ankle speeds at 90°/sec and 120°/sec. The strengthening technique was performed twice for 10 minutes each time with a 1 minute rest between sets.~The session ends with a 20-minute feedback on dynamic balance platform by carrying out exercises in which they need to reach randomly appearing targets. Subjects begin with 12 minutes the first 4 sessions, progress to 16 minutes the next 2 sessions, then 18' (2 sessions), and finally 20', if able, during the last 4 sessions.
Study NCT01926522 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Rehabilitation
Description: When needed, more than on e therapist are employed in the intervention for safety reasons.
Study NCT00892190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib (SPRYCEL)
Description: DL0 - 50 mg every 24 hours DL1 (START)- 70 mg every 24 hours DL2 - 100 mg every 24 hours DL3 - 140 mg every 24 hours
Study NCT00892190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all trans retinoic acid (VESANOID)
Description: 22.5mg/m2 every 12 hours
Study NCT03485430 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tapering
Description: Tapering with follow up by nurse at weekly basis in beginning of tapering. Tapering in an outpatient setting. Follow-up to doctor after four months.
Study NCT03672513 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Oral administration of 1 daily capsule containing lactose
Study NCT03672513 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Supplement
Description: Oral administration of 1 daily capsule containing 50 mg/day of Zn
Study NCT03672513 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium supplement
Description: Oral administration of 1 daily capsule containing 500 mg/day of Magnesium
Study NCT03075501 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paired
Description: Drug conditioning is assessed by pairing drug administration with a given context.
Study NCT03075501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stimulant or sedative
Description: CS+ for paired, CS0 for unpaired
Study NCT03075501 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Stimulant or sedative
Description: CS+ for paired, CS0 for unpaired
Study NCT03075501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: CS- for paired, CS0 for unpaired
Study NCT03075501 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: CS- for paired, CS0 for unpaired
Study NCT06217887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loxenatide Group
Description: Loxenatide will be initiated and maintained at 0.2mg once weekly until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.